UBE2T and neoplasm: They develop a nano co-delivery system combining F-127, the UBE2T inhibitor PGG, and the KRASG12D inhibitor MRTX1133, inducing significant tumor regression and durable therapeutic responses in KRASG12D-mutant PDAC.